Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 10 of 24, showing 10 Applications out of 238 total, starting on record 91, ending on 100

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

91.

ECCT/23/06/05   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Jesse Gitaka
Site(s) in Kenya
1. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. KEMRI-CRDR Siaya Clinical Research Annex (Siaya county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. University of Nairobi Clinical Research Centre (Nairobi City county)
6. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
27-10-2023 View

92.

ECCT/23/08/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Nduba Videlis
Site(s) in Kenya
1. Getrudes Children Hospital (Nairobi City county)
2. KEMRI/CRDR (Siaya county)
3. Kombewa CRC (Kisumu county)
4. Kondele Childrens Hospital (Kisumu county)
 
18-10-2023 View

93.

ECCT/23/05/07   LATA
    Long-Acting Treatment in Adolescents (LATA) A randomised open-label 2-arm 96 week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1.
 
11-09-2023 View

94.

ECCT/23/07/04   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Dr. Janet Oyieko
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county)
 
28-08-2023 View

95.

ECCT/23/05/08   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19    
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenyatta National Hospital (Nairobi City county)
4. KEMRI CCR – BUTERE SITE (Kakamega county)
5. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
6. KEMRI – AHERO Clinical Trials Unit (Kisumu county)
 
27-08-2023 View

96.

ECCT/23/04/04   AGREE
    Oral antenatal L-citrulline supplementation to reduce adverse pregnancy outcomes: a two-arm, randomized, placebo-controlled multi-site trial in Kenya   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
1. Ahero County Hospital (Kisumu county)
2. Alupe sub-county Hospital (Busia county)
3. Siaya County Referral Hospital (Siaya county)
 
24-08-2023 View

97.

ECCT/23/06/04   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE       
Principal Investigator(s)
1. Dr Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N) (Machakos county)
2. KEMRI-CRDR Siaya Clinical Research Annex (Siaya county)
3. KEMRI-Mtwapa Clinical Annex (Kilifi county)
4. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
5. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
6. University of Nairobi Clinical Research Centre (Nairobi City county)
7. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
24-08-2023 View

98.

ECCT/23/03/06   PDMC-II
    Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, multicentre, parallel-group, two-arm, randomised, double-blind superiority trial.   
Principal Investigator(s)
1. Simon Kariuki
2. Titus Kwambai
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital
 
16-08-2023 View

99.

ECCT/23/03/05   SKY-06
    A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS   PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER   
Principal Investigator(s)
1. Dr Primus Ochieng
Site(s) in Kenya
1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
11-08-2023 View

100.

ECCT/23/03/02   Sunrise-3
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19   
Principal Investigator(s)
1. Dr. Paul Yonga
2. Dr John Kinuthia
3. DR LUCAS OTIENO TINA
Site(s) in Kenya
1. Fountain Projects and Research Office, Clinical Research Centre (FOPRO-CRC) (Kisumu county)
2. KENYATTA NATIONAL HOSPITAL (Nairobi City county)
3. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
 
09-08-2023 View